



## **Therapix Biosciences completed successful studies in preclinical animal models towards a transition into clinical trials**

**The Company successfully completed the preclinical episode of the “Joint-Pharma” program, which is aimed at the development of a product combining cannabinoid substances for treating neurological disorders, with an emphasis on Tourette’s syndrome under an orphan drug designation**

Therapix Biosciences announces on February 17<sup>th</sup>, 2016 of successful results in preclinical studies it has conducted in order to confirm the “entourage effect”. The preclinical study examined synergistic effect of PEA (Palmitoylethanolamide) and THC (Tetrahydrocannabinol) combination via the measurement of behavioral parameters and pain relief features.

The study demonstrated that administering THC by itself produced limited beneficial action, in addition to side effects in most of the tested measures. However, due to the entourage effect, a combination of PEA and THC showed greater efficacy compared with the control group or groups treated with THC by itself. The combined administration of PEA together with THC significantly decreased part of the side effects attributed to THC, including uncontrollable movement and anxiety attacks in some of the tested dosages. In addition, the combined administration of PEA prevented the increase in body weight that is induced by using THC by itself. The study further indicated that the combination of PEA and THC increased the pain relief features of THC.

Therapix is acting to develop a unique treatment combining THC and PEA for treating Tourette’s syndrome. The ability of PEA to reduce and even prevent some of the typical side effects of THC, together with an increase in the therapeutic action of THC, will improve the efficacy and safety profile of the combined treatment.

Dr. Elran Haber, Therapix’s CEO, stated that “we are encouraged by the results of the latest studies which support the entourage technology. The entourage effect, first described by Prof. Raphael Mechoulam, a member of the Company’s Advisory Board, is based on the assumption that the whole is greater than the sum of its parts. The latest study conducted by the Company certainly reinforced this premise by proving the feasibility of reducing side effects and increasing the therapeutic effect of the active substances. The Company is currently acting to complete preparations for its first clinical trial”.

Therapix is engaged in a program for developing a prescribed drug product that is based on a combination of cannabinoids for Tourette's syndrome.

The choice of Tourette's syndrome, an indication allowing an accelerated regulatory path under an orphan drug program, derives from the Company's decision to engage in the development of cannabinoid-based drugs under shortened regulatory programs compared with the standard course of drug development.

Tourette's syndrome is a neurological disorder characterized by involuntary movements and vocalizations, involuntary muscular contractions (tics) and extreme stigmatization. First symptoms are diagnosed already in childhood, at the ages of 3 to 9. Data presented in a number of studies attest to the positive advantages of treating involuntary contractions by using cannabinoid substances.

Therapix is developing the drug on the basis of the "entourage effect", first published in 1998 by Prof. Raphael Mechoulam of the Hebrew University of Jerusalem. The entourage phenomenon describes a synergy created by combining cannabinoid substances or cannabinoid analogs together with existing drugs. The technology enables improving the treatment of various medical indications by reducing the standard dosages of the drug, while increasing its efficacy and improving its safety profile. The drug is developed while using formulations and a unique and improved administration method, features which, in the Company's estimation, will provide a safe and efficient treatment for Tourette's syndrome.